NAVB - Navidea Biopharmaceuticals, Inc.

NYSE American - Nasdaq Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 59.21M
Enterprise Value 35.24M
Trailing P/E N/A
Forward P/E 1-0.69
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)8.95
Price/Book (mrq)N/A
Enterprise Value/Revenue 35.10
Enterprise Value/EBITDA 6-0.55

Trading Information

Stock Price History

Beta (3Y Monthly) 1.32
52-Week Change 3-84.41%
S&P500 52-Week Change 3-0.33%
52 Week High 37.4000
52 Week Low 30.4900
50-Day Moving Average 30.5856
200-Day Moving Average 31.9578

Share Statistics

Avg Vol (3 month) 3410.45k
Avg Vol (10 day) 386.48k
Shares Outstanding 5163.62M
Float 6.47M
% Held by Insiders 121.79%
% Held by Institutions 14.85%
Shares Short (Jul 15, 2019) 4834.74k
Short Ratio (Jul 15, 2019) 40.92
Short % of Float (Jul 15, 2019) 49.36%
Short % of Shares Outstanding (Jul 15, 2019) 44.62%
Shares Short (prior month Jun 14, 2019) 4573.64k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 220/1
Last Split Date 3Apr 26, 2019

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Mar 31, 2019


Profit Margin 0.00%
Operating Margin (ttm)-940.94%

Management Effectiveness

Return on Assets (ttm)-51.98%
Return on Equity (ttm)-469.73%

Income Statement

Revenue (ttm)1.03M
Revenue Per Share (ttm)0.11
Quarterly Revenue Growth (yoy)-50.80%
Gross Profit (ttm)1.07M
Net Income Avi to Common (ttm)-11.85M
Diluted EPS (ttm)-1.3110
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)2.07M
Total Cash Per Share (mrq)0.21
Total Debt (mrq)1.13M
Total Debt/Equity (mrq)1,190.65
Current Ratio (mrq)0.95
Book Value Per Share (mrq)-0.06

Cash Flow Statement

Operating Cash Flow (ttm)4.37M
Levered Free Cash Flow (ttm)704.17k